GlassScriptPhysician profile
Husam Salem Kaileh
NPI 1700920899
$3,082.79
in general payments reported to CMS, 2019-2025
28 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $476 · 2021: $325 · 2022: $453 · 2023: $429 · 2024: $277 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,114.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $524.17 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $447.30 | 2019-2023 | Vaxneuvance, M-M-R II, Vaxelis |
| Lilly USA, LLC | $413.97 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Glaxosmithkline, LLC. | $334.01 | 2019-2024 | Bexsero, Shingrix, Pediarix |
| Pfizer INC. | $272.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $113.40 | 2024-2025 | Breztri, Airsupra |
| Sanofi Pasteur INC. | $95.36 | 2021-2025 | |
| Cranial Technologies, INC | $87.87 | 2022-2024 | Doc Band |
| Sanofi-Aventis U.S. LLC | $85.16 | 2019-2022 | |
| Exact Sciences Corporation | $83.87 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $71.28 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.83 | 2021 | |
| Dynavax Technologies Corporation | $68.68 | 2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $52.71 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $45.08 | 2022-2024 | Crysvita |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $35.82 | 2025 | |
| Mayne Pharma Commercial LLC | $33.10 | 2024 | |
| Gilead Sciences, INC. | $31.85 | 2025 | |
| Hologic Sales and Service, LLC | $31.57 | 2024 | Aptima |
| Abbott Laboratories | $31.17 | 2021 | |
| Abbvie INC. | $25.48 | 2025 | |
| Sobi, INC | $21.78 | 2021 | |
| Mannkind Corporation | $21.61 | 2019 | |
| Phadia US INC. | $20.00 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.39 | 2025 | Qelbree |
| Shire North American Group INC | $18.25 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $14.33 | 2022 | |
| Seqirus USA INC | $12.97 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Husam Kaileh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.